Saturday 17 October 2026
Export EFTR’s income statement to Excel — free account
eFFECTOR Therapeutics, Inc.
EFTR Healthcare Biotechnology
0.00
0.00
NaN
Follow EFTR
| Dec '17 | Jan '19 | Jan '20 | Dec '20 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Piotroski F-Score |
— | — | — | — | — | 3 | — | 2 | — |
P/S ratio |
— | — | 0.00 | 0.00 | — | 62.41 | 61.81 | 4.75 | — |
Altman Z-Score |
— | — | — | — | — | (1.93) | — | (9.93) | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
— | — | (13.55) | (18.18) | — | (4.83) | — | (22.76) | — |
P/Operating CF |
— | — | (263.38) | (263.38) | — | (24.97) | (24.73) | (2.71) | — |
P/B ratio |
— | — | 243,951.29 | 243,951.29 | — | 7.24 | 7.17 | 4.71 | — |
Price to Tangible BV |
— | — | 243,951.29 | 243,951.29 | — | 7.24 | 7.17 | 4.71 | — |
EV/Sales |
— | — | 0.00 | 0.00 | — | 46.99 | 46.39 | 7.75 | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
— | — | 0.00 | 0.00 | — | (3.78) | (3.74) | (1.16) | — |
EV/FCF |
— | — | 0.00 | 0.00 | — | (3.87) | (3.82) | (1.15) | — |
Quick Ratio |
— | 0.18 | 0.97 | 1.73 | 12.49 | 12.49 | 1.05 | 1.05 | 0.71 |
Current Ratio |
— | 0.23 | 1.05 | 1.89 | 13.30 | 13.30 | 1.12 | 1.12 | 0.77 |
Net Debt/EBITDA |
— | (0.42) | (0.14) | (0.15) | 0.00 | 0.97 | 0.22 | 0.22 | (0.03) |
Debt/Assets |
0.00% | 299.21% | 77.59% | 76.95% | 0.00% | 34.70% | 65.97% | 65.55% | 94.36% |
Debt/Equity |
— | (1.10) | 13.24 | (0.10) | 0.00 | 1.09 | 4.92 | 4.89 | (3.35) |
Asset Turnover |
— | 0.00 | 3.85 | 2.51 | 0.00 | 0.04 | 0.00 | 0.09 | 0.00 |
Operating CF/Net income |
— | 1.94 | 83.34 | 83.34 | (1.58) | (1.58) | 1.14 | 1.14 | 0.83 |
Capex/Depreciation |
— | 0.00 | 0.00 | (0.96) | 0.00 | 23.54 | 0.00 | (12.00) | 0.27 |
Interest Coverage |
— | (35.31) | 22.60 | 11.87 | (11,109.00) | (18.08) | (147.62) | (14.39) | (11.59) |
| — | 10.18% | (0.12%) | (0.13%) | 0.00% | (27.48%) | 0.00% | (214.02%) | 3,771.56% | |
| — | (557.80%) | 1.52% | 0.99% | 0.00% | 44.65% | 0.00% | (54.53%) | (144.34%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 102.68% | 16.96% | 2.12% | 32.13% | 32.23% | (688.70%) | (712.74%) | 615.52% |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
— | 0.00% | 51.60% | 51.98% | 0.00% | 1,395.52% | 654.66% | 656.15% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 10.35% | 10.35% | 0.00% | 935.03% | 355.84% | 355.84% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 1.19% | — | 605.59% | 0.00% | 150.13% | 0.00% |
Graham Net Nets |
— | — | 0.00 | 0.00 | — | 0.13 | 0.13 | 0.15 | — |
Graham Number |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
— | — | 0.00% | 0.00% | — | (89.15%) | (90.01%) | (121.08%) | — |
Free Cash Flow Yield |
— | — | 0.00% | 0.00% | — | (19.45%) | (19.64%) | (142.08%) | — |
Revenue per Share |
— | 0.00 | 2.81 | 744.68 | 0.00 | 2.37 | 0.09 | 2.16 | 0.00 |
Operating CF per Share |
— | (2.00) | 0.92 | 245.30 | (0.62) | (41.19) | (0.63) | (15.72) | (13.51) |
Capex per Share |
— | 0.00 | 0.00 | (2.73) | 0.00 | 0.94 | 0.00 | (0.12) | (0.04) |
Free Cash Flow per Share |
— | (2.00) | 0.92 | 242.57 | (0.62) | (40.26) | (0.63) | (15.84) | (13.56) |
Cash per Share |
— | 0.25 | 1.02 | 269.79 | 1.23 | 82.26 | 0.64 | 15.97 | 8.40 |
Shareholders Equity per Share |
— | (1.00) | 0.07 | (2,344.77) | 0.43 | 28.61 | 0.09 | 2.37 | (2.65) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (1.00) | 0.07 | (2,344.77) | 0.43 | 28.61 | 0.09 | 2.37 | (2.65) |
Free Cash Flow |
— | (27.60) | 13.84 | 13.68 | (24.89) | (24.32) | (25.94) | (26.09) | (29.65) |
Working Capital |
— | (14.66) | 0.85 | 7.80 | 48.92 | 48.92 | 2.94 | 2.94 | (5.96) |
Capital Expenditures |
— | 0.00 | (0.15) | (0.15) | (0.04) | 0.57 | (0.19) | (0.19) | (0.10) |
Net Current Asset Value |
— | (14.66) | 0.85 | (132.37) | 16.12 | 16.12 | 2.83 | 2.83 | (6.50) |
EV/EBIT |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
— | — | 0.00 | 0.00 | — | (0.40) | 0.00 | 0.05 | 0.00 |
Price to Operating Income |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.37 | 1.27 | 4.71 | 0.09 | 0.26 | 0.15 | 0.07 | (2.59) |
Cash ROIC |
— | (571.03%) | 47.45% | (13.13%) | 0.00% | (28.37%) | (52.52%) | (52.96%) | (92.76%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
— | 0.65 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | — | 0.00 | — | 0.00 | — | — |
Average Days of Payables |
— | 710.98 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | — | 0.00 | — | 0.00 | — | — |
Average Receivables |
— | — | — | — | — | — | 0.06 | — | — |
Average Payables |
— | 0.47 | 0.47 | 0.35 | 0.43 | 0.43 | 1.00 | 1.00 | 1.91 |
Average Assets |
— | 2.55 | 10.90 | 16.70 | 35.38 | 35.38 | 41.57 | 41.57 | 24.81 |
Average Common Equity |
— | (139.65) | (139.65) | (132.24) | (57.48) | (57.48) | 10.59 | 10.59 | (0.95) |
Columns are period end dates